var data={"title":"Mannitol (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mannitol (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/771531?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mannitol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Mannitol (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=mannitol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mannitol (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662085\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Osmitrol;</li>\n      <li>Resectisol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662086\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Osmitrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673467\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Diuretic, Osmotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29751752\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute renal failure:</b> IV: 0.5 to 1 g/kg/dose (Andreoli 2004); some experts recommend against routine use due to the risk of IVH in low birth weight neonates (solution is hypertonic) or the precipitation of CHF if a lack of response occurs (Andreoli 2004; Chua 2005) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673470\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mannitol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Mannitol (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> The manufacturer's labeling recommends a test dose prior to starting IV mannitol therapy in patients with marked oliguria or suspected renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute renal failure (oliguria):</b> Infants, Children, and Adolescents: IV: Initial: 0.5 to 1 g/kg/dose infused over 2 to 6 hours; usual range: 0.25 to 2 g/kg/dose; may repeat dose every 4 to 6 hours; do not repeat dose if oliguria persists. <b>Note:</b> Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Test dose (to assess adequate renal function):</i> IV: 0.2 g/kg (maximum dose: 12.5 g) over 3 to 5 minutes to produce a urine flow of at least 1 mL/kg/hour for 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intracranial pressure (ICP), reduction:</b> Infants, Children, and Adolescents: IV: Usual range: 0.25 to 1 g/kg/dose infused over 20 to 30 minutes; repeat as needed to maintain serum osmolality &lt;300 to 320 mOsm/kg (BTF [Carney 2016]; Hegenbarth 2008; Kochanek 2012). <b>Note:</b> The manufacturer's labeling allows for higher single doses up to 2 g/kg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intraocular pressure (IOP), reduction:</b> Infants, Children, and Adolescents: IV: 1 to 2 g/kg/dose or 30 to 60 g/m<sup>2</sup>/dose infused over 30 to 60 minutes administered 1 to 1.5 hours prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>IOP (traumatic hyphema), reduction:</b> Infants, Children, and Adolescents: IV: 1.5 g/kg/dose infused over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Increased intracranial pressure (ICP), cerebral edema, reduction:</b> IV: 0.25 to 1 g/kg/dose; may repeat every 6 to 8 hours as needed (BTF [Carney 2016]; Grape 2012). Some suggest maintaining serum osmolality &lt;320 mOsm/kg (Rabinstein 2006). However, this value is routinely exceeded without ill effect. A better marker for mannitol toxicity may be the serum osmole gap (or osmolal gap) and the target is &lt;18 to 20 (Erstad 2016; Garc&iacute;a-Morales 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intraocular pressure (IOP), reduction:</b> IV: 0.25 to 2 g/kg infused over 30 to 60 minutes administered 1 to 1.5 hours prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>IOP (traumatic hyphema), reduction:</b> IV: 1.5 g/kg infused over 45 minutes twice daily for IOP &gt;35 mm Hg; may administer every 8 hours in patients with extremely high pressure (Crouch 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Contraindicated in severe renal impairment. Use with caution in patients with underlying renal disease. May be used to reduce the incidence of acute tubular necrosis when administered prior to revascularization during kidney transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Osmitrol: 5% (1000 mL); 10% (500 mL); 15% (500 mL); 20% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (1000 mL [DSC]); 10% (1000 mL [DSC]); 15% (500 mL [DSC]); 20% (250 mL, 500 mL); 25% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Irrigation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Resectisol: 5% (2000 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662089\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673471\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Do not administer IM or SubQ. In-line filter set (&le;5 micron) should always be used for mannitol infusion with concentrations &ge;20% (WHO 2011); maximum concentration for administration: 25%. Inspect for crystals prior to administration; if crystals are present, redissolve by warming solution. Do not administer with blood; crenation and agglutination of red blood cells may occur. Infusion rate is dependent upon indication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute renal failure: Administer over 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cerebral edema or increased intracranial pressure: Administer over 20 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Test dose (for oliguria): Administer over 3 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662117\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Should be stored at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. In concentrations &ge;15%, crystallization may occur at low temperatures; do not use solutions that contain crystals. Heating in a hot water bath and vigorous shaking may be utilized for resolubilization. Cool solutions to body temperature before using.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irrigation: Store at room temperature of 25&deg;C (77&deg;F); excursions permitted up to 40&deg;C. Avoid excessive heat; do not warm above 150&deg;F (66&deg;C). Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673468\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Injection: Reduction of increased intracranial pressure associated with cerebral edema; reduction of increased intraocular pressure; promoting urinary excretion of toxic substances; genitourinary irrigant in transurethral prostatic resection or other transurethral surgical procedures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although FDA-labeled indications, the use of mannitol for the prevention of acute renal failure and/or promotion of diuresis is not routinely recommended (Kellum 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662080\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Osmitrol may be confused with esmolol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662107\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, cardiac failure, hypertension, hypotension, local thrombophlebitis, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bullous rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration (secondary to rapid diuresis), dilutional hyponatremia, electrolyte disturbance (increased osmolar gap), fluid and electrolyte disturbance, hypovolemia (secondary to rapid diuresis), hyperglycemia, hyperkalemia (hyperosmolality-induced), hypernatremia, hypervolemia, metabolic acidosis (dilutional), water intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, tubular necrosis (adult dose: &gt;200 g/day; serum osmolality &gt;320 mOsm/L), polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, tissue necrosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662102\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Hypersensitivity to mannitol or any component of the formulation; severe renal disease (anuria); severe dehydration; active intracranial bleeding except during craniotomy; progressive heart failure, pulmonary congestion, or renal dysfunction after mannitol administration; severe pulmonary edema or congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary irrigation solution:  Anuria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662103\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Vesicant (at concentrations &gt;5%); ensure proper catheter or needle position prior to and during IV infusion. Avoid extravasation of IV infusions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: May cause renal dysfunction especially with high doses; use caution in patients taking other nephrotoxic agents, with sepsis or preexisting renal disease. To minimize adverse renal effects, adjust to keep serum osmolality less than 320 mOsm/L. Discontinue if evidence of acute tubular necrosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cerebral edema:  In patients being treated for cerebral edema, mannitol may accumulate in the brain (causing rebound increases in intracranial pressure) if circulating for long periods of time as with continuous infusion; intermittent boluses preferred. Cardiovascular status should also be evaluated; do not administer electrolyte-free mannitol solutions with blood. If hypotension occurs, monitor cerebral perfusion pressure to ensure adequate. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adequate renal function: Should not be administered until adequacy of renal function and urine flow is established; use 1 to 2 test doses to assess renal response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29751757\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Mannitol may increase cerebral blood flow, increase the risk of postoperative bleeding in neurosurgical patients, and worsen intracranial hypertension in children who develop generalized cerebral hyperemia during the first 24 to 48 hours after traumatic brain injury. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662112\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662109\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109240&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Mannitol (Systemic) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tobramycin (Oral Inhalation): Mannitol (Systemic) may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662098\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662099\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673472\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, daily fluid I &amp; O, serum electrolytes, serum and urine osmolality; for treatment of elevated intracranial pressure, maintain serum osmolality &lt;300 to 320 mOsm/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662120\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces an osmotic diuresis by increasing the osmotic pressure of glomerular filtrate, which inhibits tubular reabsorption of water and electrolytes and increases urinary output . Mechanism of action in reduction of intracranial pressure (ICP) is less clear. However, it is thought that mannitol reduces ICP by reducing blood viscosity which transiently increases cerebral blood flow and oxygen transport and constricts pial arterioles. This in turn reduces cerebral blood volume and ICP. Furthermore, mannitol reduces ICP by withdrawing water from the brain parenchyma and excretes water in the urine (Allen 1998; BTF [Carney 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Diuresis: 1 to 3 hours; Reduction in intracranial pressure: ~15 to 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Reduction in intracranial pressure: 1.5 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 34.3 L; remains confined to extracellular space (except in extreme concentrations); does not penetrate the blood-brain barrier (generally, penetration is low)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic to glycogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.25 to 1.7 hours; 6 to 36 hours in renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~55% to 87% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28673473\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Approximate osmolarity: Mannitol 20%: 1100 mOsm/L; mannitol 25%: 1375 mOsm/L </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28662154\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mannitol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $23.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $2.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Osmitrol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (1000 mL): $54.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (500 mL): $53.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15% (500 mL): $59.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $52.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Resectisol Irrigation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (2000 mL): $11.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46972187\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ardeaosmosol MA (CZ);</li>\n      <li>Demanitol (PE);</li>\n      <li>Demanitol AL (PY);</li>\n      <li>Infusan M20 (ID);</li>\n      <li>Isotol (IT);</li>\n      <li>Mannisol (HU);</li>\n      <li>Mannits (EE);</li>\n      <li>Neurotol-M (IN);</li>\n      <li>Osmitrol (AU, IN, KW, NZ, QA, SA, SG);</li>\n      <li>Osmofundin (AT, ES, MY, RO, SG);</li>\n      <li>Osmofundina (PT);</li>\n      <li>Osmokab (MX);</li>\n      <li>Osmorin (PE, PY);</li>\n      <li>Osmosol (BD);</li>\n      <li>Osmosteril (NL);</li>\n      <li>Otsu-manitol (ID);</li>\n      <li>Renitol (PH);</li>\n      <li>Resectisol (TR);</li>\n      <li>Rezosel (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen CH and Ward JD, &ldquo;An Evidence-Based Approach to Management of Increased Intracranial Pressure,&rdquo; <i>Crit Care Clin</i>, 1998, 14(3):485-96.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andreoli SP, &quot;Acute Renal Failure in the Newborn,&quot; <i>Semin Perinatol</i>, 2004, 28(2):112-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/15200250/pubmed\" target=\"_blank\" id=\"15200250\">15200250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brain Trauma Foundation,&quot;Guidelines for the Management of Severe Traumatic Brain Injury, 4th ed,&quot; 2016. Available at https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. II. Hyperosmolar Therapy,&rdquo; <i>J Neurotrauma</i>, 2007, 24(Suppl 1):14-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/17511539/pubmed\" target=\"_blank\" id=\"17511539\">17511539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo; <i>Stroke</i>, 2007, 38(6):2001-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/17478736/pubmed\" target=\"_blank\" id=\"17478736\">17478736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chua AN and Sarwal MM, &quot;Acute Renal Failure Management in the Neonate,&quot; <i>NeoReviews</i>, 2005, 6:e369-76.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crouch ER Jr and Crouch ER, &quot;Management of Traumatic Hyphema: Therapeutic Options,&quot; <i>J Pediatr Ophthalmol Strabismus</i>, 1999, 36(5):238-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/10505828/pubmed\" target=\"_blank\" id=\"10505828\">10505828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad B, ed. <i>Critical Care Pharmacotherapy</i>. American College of Clinical Pharmacy. 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garc&iacute;a-Morales EJ, Cariappa R, Parvin CA, Scott MG, Diringer MN. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. <i>Crit Care Med</i>. 2004;32(4):986-991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/15071390/pubmed\" target=\"_blank\" id=\"15071390\">15071390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kellum JA, Cerda J, Kaplan LJ, et al, &ldquo;Fluids for Prevention and Management of Acute Kidney Injury,&rdquo; <i>Int J Art Organ</i>, 2008, 31(2):96-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/18311727/pubmed\" target=\"_blank\" id=\"18311727\">18311727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Kidney Transplantation: Principles and Practice</i>, 6th ed, Morris PJ and Knechtle SJ, eds, Philadelphia, PA: Saunders, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo; <i>Pediatr Crit Care Med</i>, 2012, 13(Suppl 1):1-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/22217782/pubmed\" target=\"_blank\" id=\"22217782\">22217782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mannitol injection [prescribing information]. Lake Forest, IL: Hospira, Inc; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, Fleisher LA, Wiener-Kronish JP, et al, eds, Miller&rsquo;s Anesthesia, 7th ed, Philadelphia: Churchill Livingstone, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabinstein AA, &quot;Treatment of Cerebral Edema,&quot; <i>Neurologist</i>, 2006, 12(2):59-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mannitol-systemic-pediatric-drug-information/abstract-text/16534443/pubmed\" target=\"_blank\" id=\"16534443\">16534443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). 18th Expert Committee on the Selection and Use of Essential Medicines: review of the role of mannitol in the therapy of children. 2011. Available at http://www.who.int/selection_medicines/committees/expert/18/applications/16_Mannitol_review_EMLc.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109240 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28662085\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28662086\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F28673467\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F29751752\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F28673470\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28662152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F28662089\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28673471\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F28662117\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28673468\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28662080\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28662107\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28662102\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28662103\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F29751757\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28662112\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28662109\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28662098\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28662099\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28673472\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28662120\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F28662122\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F28673473\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28662154\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46972187\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/109240|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mannitol-systemic-drug-information\" class=\"drug drug_general\">Mannitol (systemic): Drug information</a></li><li><a href=\"topic.htm?path=mannitol-systemic-patient-drug-information\" class=\"drug drug_patient\">Mannitol (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}